Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease
Although major advances have occurred in treating patients with hepatitis C virus (HCV) with the development of new direct-acting antivirals (DAAs), treatment of liver transplant recipients with HCV, human immunodeficiency virus (HIV) coinfection, and renal disease is challenging due to the lack of...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2016/8372835 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550877427138560 |
|---|---|
| author | Anna Maruyama Trana Hussaini Nilufar Partovi Siegfried R. Erb Vladimir Marquez Azalgara Nadia Zalunardo Neora Pick Mark Hull Eric M. Yoshida |
| author_facet | Anna Maruyama Trana Hussaini Nilufar Partovi Siegfried R. Erb Vladimir Marquez Azalgara Nadia Zalunardo Neora Pick Mark Hull Eric M. Yoshida |
| author_sort | Anna Maruyama |
| collection | DOAJ |
| description | Although major advances have occurred in treating patients with hepatitis C virus (HCV) with the development of new direct-acting antivirals (DAAs), treatment of liver transplant recipients with HCV, human immunodeficiency virus (HIV) coinfection, and renal disease is challenging due to the lack of efficacy and safety data in this population. We report a case of successful HCV therapy in a postliver transplant HIV coinfected patient, with stage 4 chronic kidney disease, using an all-oral regimen of simeprevir, sofosbuvir, and ribavirin. The 51-year-old male achieved SVR24, and no specific HIV-related or transplant-related adverse events were documented during the treatment period. The new DAAs show promise for HIV coinfected patients and those with severe to end-stage renal disease (ESRD); however, robust clinical trials or large cohort studies will need to be conducted to confirm the efficacy and safety of these newer agents in this setting. |
| format | Article |
| id | doaj-art-f38d6d8edd744d8cb88ea7c6e2b6502a |
| institution | Kabale University |
| issn | 1712-9532 1918-1493 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-f38d6d8edd744d8cb88ea7c6e2b6502a2025-02-03T06:05:38ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95321918-14932016-01-01201610.1155/2016/83728358372835Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney DiseaseAnna Maruyama0Trana Hussaini1Nilufar Partovi2Siegfried R. Erb3Vladimir Marquez Azalgara4Nadia Zalunardo5Neora Pick6Mark Hull7Eric M. Yoshida8Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, CanadaFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, CanadaFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, CanadaDivision of Gastroenterology, University of British Columbia, Vancouver, BC, CanadaDivision of Gastroenterology, University of British Columbia, Vancouver, BC, CanadaDivision of Nephrology, University of British Columbia, Vancouver, BC, CanadaDivision of AIDS, University of British Columbia, Vancouver, BC, CanadaDivision of AIDS, University of British Columbia, Vancouver, BC, CanadaDivision of Gastroenterology, University of British Columbia, Vancouver, BC, CanadaAlthough major advances have occurred in treating patients with hepatitis C virus (HCV) with the development of new direct-acting antivirals (DAAs), treatment of liver transplant recipients with HCV, human immunodeficiency virus (HIV) coinfection, and renal disease is challenging due to the lack of efficacy and safety data in this population. We report a case of successful HCV therapy in a postliver transplant HIV coinfected patient, with stage 4 chronic kidney disease, using an all-oral regimen of simeprevir, sofosbuvir, and ribavirin. The 51-year-old male achieved SVR24, and no specific HIV-related or transplant-related adverse events were documented during the treatment period. The new DAAs show promise for HIV coinfected patients and those with severe to end-stage renal disease (ESRD); however, robust clinical trials or large cohort studies will need to be conducted to confirm the efficacy and safety of these newer agents in this setting.http://dx.doi.org/10.1155/2016/8372835 |
| spellingShingle | Anna Maruyama Trana Hussaini Nilufar Partovi Siegfried R. Erb Vladimir Marquez Azalgara Nadia Zalunardo Neora Pick Mark Hull Eric M. Yoshida Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease |
| title_full | Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease |
| title_fullStr | Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease |
| title_full_unstemmed | Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease |
| title_short | Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease |
| title_sort | successful treatment of hepatitis c with simeprevir sofosbuvir and ribavirin in an hiv coinfected liver transplant patient with advanced chronic kidney disease |
| url | http://dx.doi.org/10.1155/2016/8372835 |
| work_keys_str_mv | AT annamaruyama successfultreatmentofhepatitiscwithsimeprevirsofosbuvirandribavirininanhivcoinfectedlivertransplantpatientwithadvancedchronickidneydisease AT tranahussaini successfultreatmentofhepatitiscwithsimeprevirsofosbuvirandribavirininanhivcoinfectedlivertransplantpatientwithadvancedchronickidneydisease AT nilufarpartovi successfultreatmentofhepatitiscwithsimeprevirsofosbuvirandribavirininanhivcoinfectedlivertransplantpatientwithadvancedchronickidneydisease AT siegfriedrerb successfultreatmentofhepatitiscwithsimeprevirsofosbuvirandribavirininanhivcoinfectedlivertransplantpatientwithadvancedchronickidneydisease AT vladimirmarquezazalgara successfultreatmentofhepatitiscwithsimeprevirsofosbuvirandribavirininanhivcoinfectedlivertransplantpatientwithadvancedchronickidneydisease AT nadiazalunardo successfultreatmentofhepatitiscwithsimeprevirsofosbuvirandribavirininanhivcoinfectedlivertransplantpatientwithadvancedchronickidneydisease AT neorapick successfultreatmentofhepatitiscwithsimeprevirsofosbuvirandribavirininanhivcoinfectedlivertransplantpatientwithadvancedchronickidneydisease AT markhull successfultreatmentofhepatitiscwithsimeprevirsofosbuvirandribavirininanhivcoinfectedlivertransplantpatientwithadvancedchronickidneydisease AT ericmyoshida successfultreatmentofhepatitiscwithsimeprevirsofosbuvirandribavirininanhivcoinfectedlivertransplantpatientwithadvancedchronickidneydisease |